Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Average Price Target of $7.50

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $7.50.

A number of equities research analysts have commented on CRDF shares. Wall Street Zen upgraded Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. HC Wainwright raised Cardiff Oncology from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Finally, William Blair lowered shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th.

Cardiff Oncology Stock Performance

CRDF stock opened at $0.89 on Tuesday. Cardiff Oncology has a 52-week low of $0.76 and a 52-week high of $3.31. The company’s 50 day simple moving average is $1.09 and its 200-day simple moving average is $1.30.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.06 million. On average, research analysts anticipate that Cardiff Oncology will post -0.60 EPS for the current fiscal year.

Institutional Trading of Cardiff Oncology

A number of institutional investors have recently bought and sold shares of CRDF. GoalVest Advisory LLC acquired a new position in Cardiff Oncology in the third quarter worth approximately $832,000. Engineers Gate Manager LP bought a new position in Cardiff Oncology during the second quarter valued at approximately $32,000. Squarepoint Ops LLC raised its position in Cardiff Oncology by 264.6% during the second quarter. Squarepoint Ops LLC now owns 96,090 shares of the company’s stock valued at $125,000 after acquiring an additional 69,734 shares in the last quarter. Hsbc Holdings PLC bought a new position in Cardiff Oncology during the second quarter valued at approximately $37,000. Finally, Glenview Trust Co acquired a new stake in Cardiff Oncology in the second quarter valued at approximately $56,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing cancer therapies designed to target difficult-to-treat tumors. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division and tumor growth.

Cardiff Oncology has primarily evaluated onvansertib in combination with existing treatments for patients with RAS-mutated metastatic colorectal cancer, including regimens involving chemotherapy and targeted agents.